

## Results of 2018 Annual Meeting of Stockholders

**10 May 2018 - Minnesota, United States and Melbourne, Australia** – Osprey Medical (ASX:OSP) held its Annual Meeting of Stockholders today and, in accordance with ASX Listing Rule 3.13.2, is pleased to announce that each of the resolutions put to stockholders as set forth in the Notice of Annual Meeting and Proxy Statement dated 9 April 2018 were passed.

The information required under Section 251AA of the Corporations Act is attached.

Brendan Case  
Australian Secretary

### Contact details:

#### Media

Amanda Loh  
Buchan Consulting  
T: (613) 8866 1210  
[aloh@buchanwe.com.au](mailto:aloh@buchanwe.com.au)

#### Investors

Rebecca Wilson  
Buchan Consulting  
M: (61) 417 382 391  
[rwilson@buchanwe.co.au](mailto:rwilson@buchanwe.co.au)

#### Company

Doug Schoenberg  
VP of Marketing  
T: (952) 955 8230  
[dschoenberg@ospreymed.com](mailto:dschoenberg@ospreymed.com)

### About Osprey

Osprey Medical's vision is to make heart imaging procedures safer for patients with poor kidney function. The amount of dye (contrast) used during angiographic imaging procedures increases the patient's risk for dye-related kidney damage known as Contrast Induced Acute Kidney Injury (AKI). The Company's core technologies originated from research conducted by Dr David Kaye at Melbourne's Baker Institute. Its proprietary dye reduction and monitoring technologies are designed to help physicians minimize dye usage and monitor the dose of dye real time throughout the procedure. The Company's DyeVert™ Plus System reduces contrast while maintaining image quality in a self-adjusting easy-to-use design that monitors dye usage. Osprey Medical's Board and Management are comprised of experienced and successful personnel with established track records covering medical device development, regulatory approvals, sales and marketing, and mergers-acquisitions. Osprey Medical's advisory board comprises world-recognised experts in heart and kidney diseases.

### Foreign Ownership Restriction

Osprey's CHES Depository Interests (CDIs) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (Securities Act) for offers or sales which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. The holders of Osprey's CDIs are unable to sell the CDIs into the US or to a US person unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. Hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.



ANNUAL MEETING - CDI VOTING DIRECTION  
Thursday, 10 May, 2018

As required by section 251AA(2) of the Corporations Act 2001 (Commonwealth) the following statistics are provided in respect of each resolution on the agenda.

Resolution	Manner in which the securityholder directed the proxy vote (as at proxy close):				Manner in which votes were cast in person or by proxy on a poll (where applicable)		
	Votes <i>For</i>	Votes <i>Against</i>	Votes <i>Discretionary</i>	Votes <i>Abstain</i>	<i>For</i>	<i>Against</i>	<i>Abstain **</i>
1 ELECTION OF MRS SANDRA LESENFANTS AS A CLASS III DIRECTOR	219,363,250	0	7,500	285,309	219,370,750 100.00%	0 0.00%	285,309
2A RE-ELECTION OF MR ANDREW JANE AS A CLASS II DIRECTOR	219,485,813	0	2,500	277,290	219,485,813 100.00%	0 0.00%	277,290
2B RE-ELECTION OF DR CHRISTOPHER NAVE AS A CLASS II DIRECTOR	219,485,813	0	2,500	277,290	219,485,813 100.00%	0 0.00%	277,290
3 RATIFICATION AND APPROVAL OF PRIOR ISSUE OF CDIS	108,310,902	324,947	18,950	19,702,102	108,329,852 99.70%	324,947 0.30%	19,702,102
4 APPROVAL OF 10% PLACEMENT FACILITY	217,023,088	2,563,667	16,450	167,220	217,039,538 98.83%	2,563,667 1.17%	167,220
5 INCREASE IN THE SHARE POOL UNDER THE 2016 STOCK INCENTIVE PLAN	187,285,824	32,259,347	16,450	198,804	187,302,274 85.31%	32,259,347 14.69%	198,804
6 GRANT OF OPTIONS TO MR JOHN ERB, CHAIRMAN OF THE COMPANY	176,633,694	42,887,867	16,450	222,414	176,650,144 80.46%	42,887,867 19.54%	222,414
7 GRANT OF OPTIONS TO MRS SANDRA LESENFANTS, A DIRECTOR OF THE COMPANY	177,467,621	42,053,940	16,450	222,414	177,484,071 80.84%	42,053,940 19.16%	222,414

\*\* - Note that votes relating to a person who abstains on an item are not counted in determining whether or not the required majority of votes were cast for or against that item



ANNUAL MEETING - CDI VOTING DIRECTION  
Thursday, 10 May, 2018

As required by section 251AA(2) of the Corporations Act 2001 (Commonwealth) the following statistics are provided in respect of each resolution on the agenda.

Resolution	Manner in which the securityholder directed the proxy vote (as at proxy close):				Manner in which votes were cast in person or by proxy on a poll (where applicable)		
	Votes <i>For</i>	Votes <i>Against</i>	Votes <i>Discretionary</i>	Votes <i>Abstain</i>	<i>For</i>	<i>Against</i>	<i>Abstain **</i>
8 GRANT OF OPTIONS TO MR NEVILLE MITCHELL, A DIRECTOR OF THE COMPANY	177,420,241	42,052,640	16,450	271,094	177,436,691 80.84%	42,052,640 19.16%	271,094
9 GRANT OF OPTIONS TO MR MICHAEL MCCORMICK, PRESIDENT & CEO AND A DIRECTOR OF THE COMPANY	184,551,638	34,920,044	22,649	266,094	184,574,287 84.09%	34,920,044 15.91%	266,094

\*\* - Note that votes relating to a person who abstains on an item are not counted in determining whether or not the required majority of votes were cast for or against that item